UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: liver disease

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.

Read More

Inhibiting NOX enzymes to treat multiple diseases with high medical need

NOX enzymes are a family of enzymes which amplify multiple signaling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.

Read More

Stem cell based anti-NASH drug testing: a pragmatic approach for a complex disease

Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.

Read More

The Genetics of progressive NAFLD

Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.

Read More

A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD

Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.

Read More

Is Not Dying Yet on your bucket list?

The Fatty Liver Foundation exists because I was not willing to be a well behaved member of the parade of misery that liver disease is becoming for our society. My bucket list includes not dying of liver disease.

Read More

The race to find a treatment for NASH; what’s the big hold up?

If I were to tell you that there was a multi-million pound race to help more than 1 billion people – you would call me crazy, but believe it or not, it’s actually true! In recognition of International NASH Day, I’m asking what’s the big hold up when it comes to treating NASH?

Read More

The Global NASH Congress – Slide release

An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.

Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive